Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Seth Hendrix

Physician Assistant, Medical Shreveport, LA Physician Assistant

NPI 1821499823 CMS profile 11146396

820 Jordan St Ste 201, Shreveport, LA 71101

Open in the dashboard

General payments

$12,295

644 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Seth Hendrix of Shreveport, LA is reported in the CMS Open Payments database as having received $12,295 across 644 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,609 134
2024 General $2,498 132
2023 General $2,049 106
2022 General $2,549 137
2021 General $2,589 135

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Seth Hendrix
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Seth Hendrix were reported at $2,609. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Seth Hendrix Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,589 $156 $41–$563 $132
2022 $2,549 $185 $55–$649 $149
2023 $2,049 $199 $58–$717 $160
2024 $2,498 $206 $62–$740 $164
2025 $2,609 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Amgen Inc. $4,225 234 payments
  2. AbbVie, Inc. $2,653 135 payments
  3. Novartis Pharmaceuticals Corporation $1,208 73 payments
  4. Janssen Biotech, Inc. $835 42 payments
  5. UCB, Inc. $834 37 payments
  6. Mallinckrodt Hospital Products Inc. $573 21 payments
  7. E.R. Squibb & Sons, L.L.C. $290 16 payments
  8. Lilly USA, LLC $199 11 payments
  9. Pfizer Inc. $197 13 payments
  10. GlaxoSmithKline, LLC. $163 9 payments
  11. Other $1,117 53 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,235 643 payments
  2. Education $60 1 payment
Products named General payments · program years 2021–2025
  1. RINVOQ $1,969 106 payments
  2. Otezla $1,744 104 payments
  3. Enbrel Inflammation $1,741 82 payments
  4. Enbrel Inflammation $1,224 85 payments
  5. COSENTYX Dermatology $802 50 payments
  6. TAVNEOS $638 36 payments
  7. TREMFYA $607 27 payments
  8. ACTHAR $573 21 payments
  9. COSENTYX Immunology $556 32 payments
  10. SIMPONI ARIA $545 34 payments
  11. Other $4,663 243 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

769

Median for Physician Assistant: 241

Drug cost

$16,368

Median for Physician Assistant: $4,110

Branded share of claims

24.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydroxychloroquine Sulfate Generic 168 $5,032
Leflunomide Generic 118 $4,209
Methotrexate Methotrexate Sodium Brand 187 $3,027
Sulfasalazine Generic 132 $2,314
Allopurinol Generic 57 $618
Etodolac Generic 14 $499
Celecoxib Generic 19 $234
Meloxicam Generic 35 $165
Alendronate Sodium Generic 19 $156
Prednisone Generic 20 $115

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$27,554

Of which drugs: $320

Medicare patients

182

Average age 73

Services billed

759

151 women, 31 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 40%
Diabetes 29%
Ischemic heart disease 24%
Depression 24%
COPD 16%
Atrial fibrillation 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 19 43 $242

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Enbrel
  • Amgen Inc. $422
$422 — —
RINVOQ
  • AbbVie, Inc. $307
$307 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $297
$297 — —
Otezla
  • Amgen Inc. $238
$238 — —
ACTHAR
  • Mallinckrodt Hospital Products Inc. $227
$227 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

644 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record